A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Wei-Sen Lam,Jenette Creaney,Fred K. Chen, Wee Loong Chin,Sanjeevan Muruganandan,Sukanya Arunachalam,Mary S. Attia,Catherine Read,Kevin Murray,Michael Millward,Jon Spiro,Aron Chakera,Y.C. Gary Lee,Anna K. Nowak

Lung Cancer（2020）

引用 15|浏览37

暂无评分

摘要

•Patients with previously treated pleural mesothelioma were treated with AZD4547.•12 % of patients were progression free at 6 months.•There were no confirmed objective responses to treatment.•There was no association between tumour BAP1 protein expression and treatment outcome.•This study did not meet its primary endpoint.

查看译文

关键词

Fibroblast-growth-factor receptor,Malignant pleural mesothelioma,AZD4547,BAP1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要